Daily Cosmetic Research Analysis
Analyzed 4 papers and selected 3 impactful papers.
Summary
Mechanistic and clinical advances in cosmetic-related research include an exosome-mediated lncRNA pathway that drives hypertrophic scarring, bioengineering of yeast to markedly increase phytoceramide content for skin barrier applications, and a decade-long ophthalmic cohort defining predictors of anatomical success after fornix reconstruction. Together, these studies bridge molecular targets, sustainable ingredient production, and surgical decision-making.
Research Themes
- Exosome/lncRNA signaling driving skin fibrosis
- Biotechnological production of cosmetic lipids (phytoceramides)
- Ocular surface reconstructive surgery outcomes and predictors
Selected Articles
1. Keratinocyte-derived exosomes serve as an active messenger platform for LINC01605 to amplify TGF-β1-induced fibroblasts activation.
The study identifies an exosome-mediated lncRNA pathway whereby TGF-β1-stimulated keratinocytes package and deliver linc01605 to dermal fibroblasts, enhancing proliferation, migration, and collagen I expression. linc01605 sponges miR-370-3p to upregulate TGFBR2 and amplify canonical TGF-β1/Smads signaling, defining a targetable axis in hypertrophic scarring.
Impact: Revealing an exosome–lncRNA–miRNA–receptor axis links epithelial signaling to fibroblast activation and fibrosis, opening avenues for anti-fibrotic intervention at multiple nodes (exosome cargo, lncRNA, or receptor).
Clinical Implications: While preclinical, the linc01605/miR-370-3p/TGFBR2 axis suggests biomarker and therapeutic targets for hypertrophic scarring, including exosome-cargo modulation and nucleic acid therapeutics.
Key Findings
- TGF-β1-stimulated keratinocyte exosomes enhanced dermal fibroblast proliferation, migration, and COL1A1 expression.
- Exosomal linc01605 was identified as the primary mediator of profibrotic activity.
- linc01605 acted as a ceRNA for miR-370-3p, relieving repression of TGFBR2 and amplifying TGF-β1/Smads signaling.
- Defines a novel pathogenic pathway linking epithelial exosome cargo to fibroblast activation in hypertrophic scarring.
Methodological Strengths
- Mechanistic dissection of an exosome–lncRNA–miRNA pathway with defined molecular targets (miR-370-3p, TGFBR2).
- Functional readouts in human dermal fibroblasts (proliferation, migration, collagen I expression) aligned with fibrosis biology.
Limitations
- Predominantly in vitro; no in vivo or clinical validation reported.
- Extent of exosome heterogeneity and cargo specificity in patient tissues remains unaddressed.
Future Directions: Validate the linc01605/miR-370-3p/TGFBR2 axis in animal models and clinical samples; develop delivery systems or inhibitors targeting exosome cargo or lncRNA interactions.
Hypertrophic scarring (HS) represents a proliferative disorder that emerges due to aberrant wound healing processes and is characterized by the excessive accumulation of extracellular matrix components. Recent research has highlighted the pivotal role of exosomes-nanoscale extracellular vesicles-as crucial mediators of intercellular communication in both tissue repair and pathological states. This study investigates the mechanism by which TGF-β1 modulates the cargo of keratinocyte-derived exosomes to promote the transfer of the long non-coding RNA linc01605. The results reveal that exosomes secreted by TGF-β1-stimulated keratinocytes exhibit heightened profibrotic activity. Upon internalization by human dermal fibroblasts (HDFs), these exosomes markedly enhance cellular proliferation, migration, and collagen I (COL1A1) expression. linc01605, encapsulated within these exosomes, has been identified as the primary molecular mediator. Mechanistically, linc01605 functions as a competitive endogenous RNA that binds miR-370-3p, thereby alleviating the repression of TGFBR2 expression and amplifying the canonical TGF-β1/Smads signaling pathway. In summary, this work elucidates a novel pathogenic pathway in which TGF-β1-induced keratinocyte-derived exosomes mediate the delivery of HS-associated linc01605 to drive fibrosis. These findings not only clarify a fundamental mechanism underlying HS pathogenesis but also reveal potential therapeutic targets for the development of innovative anti-fibrotic strategies.
2. Metabolic engineering of Saccharomyces cerevisiae sphingolipid pathways for enhanced phytoceramide production.
Targeted rewiring of yeast sphingolipid metabolism—especially SCS7 deletion—achieved a 15-fold increase in phytoceramide abundance and raised their share of the ceramide pool to 75%. SUR2 overexpression elevated phytoceramides to 46%, while combining SCS7 deletion with SUR2 overexpression offered no additive benefit, indicating intrinsic regulatory constraints.
Impact: Provides a clear, quantitative roadmap to engineer phytoceramide-enriched strains, addressing a bottleneck in sustainable cosmetic/pharmaceutical lipid supply.
Clinical Implications: Although preclinical, scalable microbial production of phytoceramides could improve access and consistency of skin-barrier lipids in dermatologic and cosmetic formulations.
Key Findings
- SCS7 deletion increased total phytoceramide abundance ~15-fold versus wild type and raised their fraction to 75% of the ceramide pool.
- SUR2 overexpression increased phytoceramide fraction to 46%, yet combining SCS7 deletion and SUR2 overexpression showed no additive effect.
- Residual hydroxylated ceramides indicate intrinsic regulatory constraints, consistent with a bypass mechanism using pre-hydroxylated acyl-CoA.
- Comprehensive lipidomics discriminated engineered from wild-type strains and pinpointed genotypes with maximal phytoceramide accumulation.
Methodological Strengths
- Integrated metabolic engineering with quantitative lipidomics across multiple genotypes and strategies.
- Clear benchmarking against wild type enabling precise assessment of flux redirection.
Limitations
- Scalability and bioprocess yields were not reported.
- No assessment of bioactivity or formulation performance of the engineered phytoceramides.
Future Directions: Optimize fermentation and downstream processing for yield and purity; evaluate bioactivity and safety of produced phytoceramides in skin models.
Phytoceramides are essential sphingolipids that support skin barrier integrity and hydration, making them valuable for cosmetic and pharmaceutical applications. However, their intricate structures and low natural abundance pose significant challenges for scalable production. Here, we present an integrated metabolic engineering and lipidomics study aimed at enhancing phytoceramide production in Saccharomyces cerevisiae. We implemented three strategies: (i) overexpression of SUR2 (sphinganine C4-hydroxylase) to boost phytosphingolipid formation; (ii) deletion of SCS7 (ceramide α-hydroxylase) to redirect flux toward non-hydroxylated phytoceramides; and (iii) overexpression of ISC1 (inositol phosphosphingolipid phospholipase) to recycle complex sphingolipids into ceramide pools. SUR2 overexpression showed the highest transcript levels, whereas lipidomics revealed that scs7Δ produced the highest phytoceramide enrichment with a 15-fold increase in phytoceramide abundance relative to the wild type. In terms of relative abundance within the quantified ceramide pool, phytoceramides increased from 5% in wild type to 46% in the SUR2-OE strain and 75% in the scs7Δ strain. The combined scs7Δ SUR2-OE strain did not exhibit additive metabolic effects on the lipid profile. The presence of residual hydroxylated ceramides indicated intrinsic regulatory constraints, aligning with the bypass mechanism proposed here whereby ceramide synthases can use pre-hydroxylated acyl-CoA. Importantly, this work contributes a comprehensive lipidomic profiling of S. cerevisiae, enabling clear discrimination between engineered and wild type strains and identification of genotypes exerting the greatest impact on phytoceramide accumulation. This approach advances sphingolipid pathway modulation and positions S. cerevisiae as a valuable model for studying phytoceramide-focused remodeling.
3. Symblepharon Release and Fornix Reconstruction after Ocular Chemical Injury: Outcomes from a Decade-Long Clinical Experience.
In a 10-year retrospective cohort (125 fornices), symblepharon release with fornix reconstruction achieved 61.6% anatomical success after the first procedure and 84.8% after final reconstruction. Symblepharon grade independently predicted outcomes, and delayed epithelialization signaled poorer prognosis; cosmetic and visual rehabilitation were variably limited by comorbidities.
Impact: Provides large-scale, real-world benchmarks and actionable predictors (symblepharon grade, early epithelialization) to guide surgical planning and postoperative monitoring.
Clinical Implications: Use symblepharon severity for risk stratification and counseling; monitor early epithelialization closely to anticipate failure and tailor adjunctive therapies.
Key Findings
- Anatomical success was 61.6% after first SR-FR and 84.8% after final reconstruction.
- Symblepharon grade independently predicted poorer anatomical outcomes (multivariate p=0.005); severe cases needed more repeat attempts (p=0.027).
- Delayed epithelial healing independently associated with poorer outcomes (p=0.011); faster healing associated with improved outcomes (p=0.046).
- Age, gender, chemical type, mitomycin-C use, and fornix-forming sutures were not significant predictors.
Methodological Strengths
- Large single-center cohort over a decade with standardized anatomical and cosmetic outcome reporting.
- Multivariate ordinal logistic regression to adjust for confounders.
Limitations
- Retrospective design with potential selection and information biases.
- Heterogeneity in techniques and adjuncts over a decade; limited generalizability beyond a tertiary center.
Future Directions: Prospective, standardized protocols to validate predictors; trials of strategies to accelerate epithelialization and improve anatomical durability.
PURPOSE: To evaluate anatomical, visual and cosmetic rehabilitation outcomes of symblepharon release with fornix reconstruction (SR-FR) in eyes with chronic chemical injury and identify factors influencing surgical success. METHODS: Retrospective observational study of patients undergoing SR-FR for chemical injury-related symblepharon over 10 years at a tertiary eye care centre. Symblepharon severity, surgical techniques, epithelial healing and demographics were recorded. Anatomical (success, partial success and failure), visual rehabilitation and cosmetic rehabilitation outcomes were analysed. Multivariate ordinal logistic regression identified factors associated with anatomical outcome. RESULTS: The study involved 125 fornices in 118 patients. Median age at injury was 7 years (IQR 4-19) and at SR-FR 12 years (IQR 5-24), with a median follow-up of 15 months (IQR 8-36). Successful anatomical outcome was achieved in 61.6% after the first procedure, increasing to 84.8% after final reconstruction. Severe symblepharon was associated with lower success rates and greater need for repeat attempts (p=0.027). On multivariate analysis, symblepharon grade was an independent predictor of anatomical outcome (p=0.005), while epithelial healing was associated with improved outcome (p=0.046); delayed epithelial healing was independently associated with poorer outcome (p=0.011); age, gender, chemical type, mitomycin-C use and fornix-forming sutures were not significant. Visual improvement was independent of anatomical success and primarily limited by ocular comorbidities. CONCLUSIONS: SR-FR is an effective approach for anatomical restoration. Symblepharon severity is an independent predictor of outcome, while delayed epithelialisation is a clinically relevant early postoperative indicator of poorer outcomes. Visual recovery is largely determined by associated ocular comorbidities.